ScholarIQanswers from OpenAlex & ORCID
Mátyás Keltai
ResearcherPublications, citations & collaboration network
Mátyás Keltai is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Mátyás Keltai have?
ScholarIQindexed works
Mátyás Keltai has 162 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Mátyás Keltai have?
ScholarIQcitation count
Mátyás Keltai has 25,788 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Mátyás Keltai?
ScholarIQh-index
Mátyás Keltai has an h-index of 53 in OpenAlex.
What is the i10-index of Mátyás Keltai?
ScholarIQi10-index
Mátyás Keltai has an i10-index of 84 in OpenAlex.
What is the ORCID of Mátyás Keltai?
ScholarIQorcid
The ORCID for Mátyás Keltai is on the source record.
What is the OpenAlex record for Mátyás Keltai?
ScholarIQopenalex
The OpenAlex for Mátyás Keltai is on the source record.
What are the most-cited papers on Mátyás Keltai?
ScholarIQmost cited works
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, Rafael Díaz, Mark Lakshmanan, Prem Pais, Jeffrey L. Probstfield, Jeffrey S. Riesmeyer, Matthew C. Riddle, Lars Rydén, Denis Xavier, Charles Atisso, Leanne Dyal, Stephanie Hall, Rao Ps, G.C. Wong, Álvaro Avezum, Jan Basile, Namsik Chung, Ignacio Conget, William C. Cushman, Edward Franek, Nicolae Hâncu, M Hanefeld, Shaun Holt, Petr Janský, Mátyás Keltai, Fernando Laņas, Lawrence A. Leiter, Patricio López‐Jaramillo, Ernesto Muñoz, Valdis Pīrāgs, Nana Pogosova, Peter Raubenheimer, Jonathan E. Shaw, Wayne Huey‐Herng Sheu, Theodora Temelkova‐Kurktschiev, Mercedes Abella, Andrea Alebuena, Sandra Almagro, Eduardo Amoroso, Paula Anadon, Elizabeth Andreu, Guillermo Aristimuño, Maria Arzadun, María Antonietta Barbieri, Raúl Barcudi, Ines Bartolacci, Gabriel Bolobanich, Anselmo P. Bordonava, Miguel Bustamante Labarta, B. Bustos, Alberto Caccavo, Alejandra Camino, María del Rocío Cantero, Maria Carignano, Luis R Cartasegna, Marcela Cipullo, Víctor Commendatore, Victoria Conosciuto, Osvaldo Costamagna, Claudia A. Crespo, Jose Cuello, Carlos Alberto Cuneo, Sandra Cusimano, Sofia Dean, Claudio Fabián Dituro, Andrea Domínguez, Miguel Farah, Alberto Fernandez, Florencia Fernandez, Adriana Cristina Ferrari, Patricia Flammia, José Antonio Fuentealba, Karina Beatriz Gallardo, C. Perez Garcia, Ruben Garcia Duran, Marcelo Garrido, Rodolfo Gavícola, Claudio Gerbaudo, Graciela Gilli, Ana Paula Giotto, Pedro Godoy Bolzán, Oscar Gómez Vilamajó, Fernando Guerlloy, Cristian Guridi, Narcisa Gutierrez Garrido, Eduardo Hasbani, Sonia Hermida, Miguel Hominal, Adrian D. Hrabar, Adrián Ingaramo, Alejandra Izzicupo, Mario Krynski, Mariana Lagrutta, Paulina Virginia Lanchiotti, Maria Langhe, Veronica Leonard, Javier Llanos, Ricardo López Santi
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
John W. Eikelboom, Stuart J. Connolly, Jackie Bosch, Gilles R. Dagenais, Robert G. Hart, Olga Shestakovska, Rafael Díaz, Marco Alings, Eva Lonn, Sonia S. Anand, Petr Widimský, Masatsugu Hori, Álvaro Avezum, Leopoldo Soares Piegas, Kelley R. Branch, Jeffrey L. Probstfield, Deepak L. Bhatt, Jun Zhu, Yan Liang, Aldo P. Maggioni, Patricio López‐Jaramillo, Martin O’Donnell, Ajay K. Kakkar, Keith A.A. Fox, Alexander Parkhomenko, Georg Ertl, Stefan Störk, Mátyás Keltai, Lars Rydén, Nana Pogosova, Antonio L Dans, Fernando Laņas, Patrick Commerford, Christian Torp‐Pedersen, Tomek J. Guzik, Peter Verhamme, Dragoş Vinereanu, Jae‐Hyung Kim, Andrew M. Tonkin, Basil S. Lewis, Camilo Félix, Khalid Yusoff, Philippe Gabríel Steg, Kaj Metsärinne, Nancy Cook Bruns, Frank Misselwitz, Edmond Chen, Darryl P. Leong, Salim Yusuf
Initial Invasive or Conservative Strategy for Stable Coronary Disease
David J. Maron, Judith S. Hochman, Harmony R. Reynolds, Sripal Bangalore, Sean M. O’Brien, William E. Boden, Bernard Chaitman, Roxy Senior, José López-Sendón, Karen P. Alexander, Renato D. Lópes, Leslee J. Shaw, Jeffrey S. Berger, Jonathan Newman, Mandeep S. Sidhu, Shaun G. Goodman, Witold Rużyłło, Gilbert Gosselin, Aldo P. Maggioni, Harvey D. White, Balram Bhargava, James K. Min, G.B. John Mancini, Daniel S. Berman, Michael H. Picard, Raymond Y. Kwong, Ziad A. Ali, Daniel B. Mark, John A. Spertus, M.N. Krishnan, Ahmed Elghamaz, Nagaraja Moorthy, Whady Hueb, Marcin Demkow, Kreton Mavromatis, O.L. Bockeria, Jesús Peteiro, Todd D. Miller, Hanna Szwed, Rolf Doerr, Mátyás Keltai, Joseph B. Selvanayagam, Philippe Gabríel Steg, Claes Held, Shun Kohsaka, Stavroula Mavromichalis, Ruth Kirby, Neal Jeffries, Frank E. Harrell, Frank W. Rockhold, Samuel Broderick, T. Bruce Ferguson, David O. Williams, Robert A. Harrington, Gregg W. Stone, Yves Rosenberg
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
Johannes F.E. Mann, Roland E. Schmieder, Matthew McQueen, Leanne Dyal, Helmut Schumacher, Janice Pogue, Xingyu Wang, Aldo P. Maggioni, Andrzej Budaj, S Chaithiraphan, Kenneth Dickstein, Mátyás Keltai, Kaj Metsärinne, Ali Oto, Alexander Parkhomenko, Leopoldo Soares Piegas, Tage Lysbo Svendsen, Koon Teo, Salim Yusuf
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
John H. Alexander, Renato D. Lópes, Stefan James, Rakhi Kilaru, Yaohua He, Puneet Mohan, Deepak L. Bhatt, Shaun G. Goodman, Freek W.A. Verheugt, Marcus Flather, Kurt Huber, Danny Liaw, Steen Husted, José López‐Sendón, Raffaele De Caterina, Petr Janský, Harald Darius, Dragoş Vinereanu, Jan H. Cornel, Frank Cools, Dan Atar, José L. Leiva-Pons, Mátyás Keltai, Hisao Ogawa, Prem Pais, Alexander Parkhomenko, Witold Rużyłło, Rafael Díaz, Harvey D. White, Mikhail Ruda, Margarida Geraldes, Jack Lawrence, Robert A. Harrington, Lars Wallentin